A correlation between phenotypical tumor characteristics, quantitative classical immunohistochemistry (IHC), and recurrence score (RS) from Oncotype DX results was used to develop a decision supporting system for clinical use. We created a freely available nomogram based on quantitative IHC results that allows prediction of RS ≤ 25 or ≤ 20. Prospective studies will test this application in clinical practice.
Marazzi, F., Barone, R., Masiello, V., Magri, V., Mule, A., Santoro, A., Cacciatori, F., Boldrini, L., Franceschini, G., Moschella, F., Naso, G., Tomao, S., Gambacorta, M. A., Mantini, G., Masetti, R., Smaniotto, D., Valentini, V., Oncotype DX Predictive Nomogram for Recurrence Score Output: The Novel System ADAPTED01 Based on Quantitative Immunochemistry Analysis, <<CLINICAL BREAST CANCER>>, 2020; 20 (5): e600-e611. [doi:10.1016/j.clbc.2020.04.012] [http://hdl.handle.net/10807/198612]
Oncotype DX Predictive Nomogram for Recurrence Score Output: The Novel System ADAPTED01 Based on Quantitative Immunochemistry Analysis
Marazzi, Fabio;Santoro, Angela;Boldrini, Luca;Franceschini, Gianluca;Gambacorta, Maria Antonietta;Mantini, Giovanna;Masetti, Riccardo;Smaniotto, Daniela;Valentini, Vincenzo
2020
Abstract
A correlation between phenotypical tumor characteristics, quantitative classical immunohistochemistry (IHC), and recurrence score (RS) from Oncotype DX results was used to develop a decision supporting system for clinical use. We created a freely available nomogram based on quantitative IHC results that allows prediction of RS ≤ 25 or ≤ 20. Prospective studies will test this application in clinical practice.
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
